|
|
Article: Altus Pharmaceuticals Announces Presentation of ALTU-238 Phase II Data at International Congress of Growth Hormone and Insulin-Like Growth Factor Research Societies.
- Article from:
- Business Wire
- Article date:
- November 13, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CAMBRIDGE, Mass. -- Altus Pharmaceuticals Inc. (NASDAQ: ALTU), a biopharmaceutical company focused on oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders, announced today the presentation of results from its Phase II study of its product candidate ALTU-238 at The Third International Congress of the Growth Hormone Research Society and the Insulin-like Growth Factor Research Society, which is taking place this week in Kobe, Japan. ALTU-238 is being developed as a subcutaneously administered, once-per-week formulation of human growth hormone that employs AltuseIU proprietary protein crystallization and formulation technology.
...